Technical Analysis for IPSEF - Ipsen Promesses

Grade Last Price % Change Price Change
grade C 102.5728 -18.11% -22.6772
IPSEF closed down 18.11 percent on Wednesday, October 23, 2019, on 60 percent of normal volume. The bears made the stock sink to a new 52-week low.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A N/A N/A
See historical IPSEF trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Hot IPO Pullback Bullish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
New 52 Week Low Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Gapped Down Weakness 0.00%
New 52 Week Closing Low Bearish -18.11%
Hot IPO Pullback Bullish Swing Setup -18.11%
Narrow Range Bar Range Contraction -18.11%
New 52 Week Low Weakness -18.11%

Older signals for IPSEF ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Ipsen S.A. operates as a biopharmaceutical company worldwide. It operates in two segments, Specialty Care and Consumer Healthcare. The company offers drugs in the areas of oncology, neuroscience, pituitary pathologies and growth disorders, gastrointestinal disorders, neurodegenerative pathologies, and rheumatology. Its products include Somatuline for neuroendocrine tumors and acromegaly; Cabometyx to treat renal cell and second-line hepatocellular carcinoma; Onivyde for metastatic pancreatic cancer; Decapeptyl to treat advanced metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, female sterility, and early stage breast cancer; and Dysport for motor muscular disorders and medical aesthetics. The company also provides NutropinAq to treat growth failure in children due to growth hormone deficiency, turner syndrome, or chronic renal failure, as well as GH deficiency in adults; and Increlex for long-term treatment of growth failure in children and adolescents. In addition, it offers Smecta for the treatment of chronic and acute diarrhea, and pain linked to oesogastroduodenal conditions and colic; Forlax for constipation; and Fortrans/Eziclen for intestinal cleaning; Etiasa for inflammatory bowel diseases; and Tanakan to treat mild cognitive impairment related to age, pathophysiological deficiencies, vertigo, retinal deficits, acute or chronic hearing impairment, and tinnitus. Further, the company provides Adenuric for chronic hyperuricaemia; Prontalgine, an analgesic to treat moderate to severe pain; Buscopan, an antispasmodic; Suppositoria Glycerini, a laxative; and Mucothiol and Mucodyne, which are expectorants for cough and flu. The company has a strategic agreement with Arix Bioscience plc; and a global licensing and joint development agreement with The University of Texas MD Anderson Cancer Center. Ipsen S.A. was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy S.A.
Medicine Health RTT Cancer Biopharmaceutical Clinical Medicine Pain Neuroscience Cough Constipation Hepatocellular Carcinoma Kidney Uterine Fibroids Chronic Condition Chronic Renal Failure Flu Gastrointestinal Disorders Growth Hormone Therapy Neuroendocrine Tumors Texas Md Anderson Cancer Center Tinnitus University Of Texas Acromegaly Early Stage Breast Cancer Endometriosis Inflammatory Bowel Diseases University Of Texas Md Anderson Cancer Center Uterine Fibroid Vertigo Mild Cognitive Impairment
Is IPSEF a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 0 bearish and 5 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Indicators
Indicator Value
52 Week High 140.3843
52 Week Low 102.5728
Average Volume 333
200-Day Moving Average 0.0
50-Day Moving Average 0.0
20-Day Moving Average 0.0
10-Day Moving Average 0.0
Average True Range 0.0
ADX 0.0
+DI 0.0
-DI 0.0
Chandelier Exit (Long, 3 ATRs ) N/A
Chandelier Exit (Short, 3 ATRs ) N/A
Upper Bollinger Band 0.0
Lower Bollinger Band 0.0
Percent B (%b) 0.0
BandWidth 0.0
MACD Line 0.0
MACD Signal Line 0.0
MACD Histogram 0.0
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 102.5728
Resistance 3 (R3) 102.5728 102.5728 102.5728
Resistance 2 (R2) 102.5728 102.5728 102.5728 102.5728
Resistance 1 (R1) 102.5728 102.5728 102.5728 102.5728 102.5728
Pivot Point 102.5728 102.5728 102.5728 102.5728 102.5728
Support 1 (S1) 102.5728 102.5728 102.5728 102.5728 102.5728
Support 2 (S2) 102.5728 102.5728 102.5728 102.5728
Support 3 (S3) 102.5728 102.5728 102.5728
Support 4 (S4) 102.5728